25 September 2008
Interim Results For the Six Months Ended 30 June 2008.
23 July 2008
Strategic Review and Board Changes
20 May 2008
Curidium Announces conference
dates
20 May 2008
Curidium Announces Directors' Purchase of Company Shares.
12 May 2008
Curidium Announces
Preliminary results for the year ended 31 December 2007
29 January 2008
Curidium Announces Directors' Purchase of Company Shares.
23 January 2008
Change of Adviser.
14 December 2007
Curidium To Present At The 3rd UK Biotechnology Company Showcase.
05 December 2007
Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment
Focus on Major Depressive Disorder-
31 October 2007
Curidium To Present At The Acumen Biofin Rodman
& Renshaw 9th Annual Healthcare
Conference.
22 October 2007
Curidium To Present At The Neurodrug 2007
Conference.
15 October 2007
Curidium To Present At The 6th Annual Evolution Summit 2007.
01 October 2007
Curidium Founder Assumes Chief Scientific Officer Position. Increased Focus to Benefit Company’s Key Scientific Assets.
27 September 2007
Curidium Announces Interim Results.
24 September 2007
Curidium To Present At UBS 2007 Global Life Sciences
Conference.
30 July 2007
Curidium Closes On £2.5 Million Financing. New
funding to accelerate Company’s Growth Strategy.
(PDF document)
16 July 2007
Curidium Trademarks “PsychINDx” As Name For Its Blood Diagnostic Test For Schizophrenia/Bipolar Disorder Patient Subgroups.
(Word document)
14 May 2007
Curidium Develops Blood Diagnostic Test For Schizophrenia/Bipolar Disorder Patient Subgroups. (Word document)
10 May 2007
Curidium To Present At Rodman & Renshaw 4th Annual Global Healthcare Conference. (Word document)
30 April 2007
Curidium Announces Preliminary Results For The Financial Year Ended 31 December 2006. (PDF document)
26 April 2007
Curidium Announces Changes To Board Of Directors. (Word document)
21 March 2007
Curidium Discovers Significant Diagnostic Gene Expression
Profiles In Blood Of Schizophrenia And Bipolar Patients. (Word document)
14 March 2007
Curidium To Present At Clinical Biomarker Summit.
(Word document)
13 March 2007
Curidium Confirms In Second Brain Study Significantly
Different Patient Subgroups In Schizophrenia And Bipolar Disorder.
(Word document)
05 March 2007
Curidium Discovers Significantly Different Patient
Subgroups In Schizophrenia And Bipolar Disorder. (Word document)
15 December 2006
Curidium Expands Its Development Programmes In Schizophrenia And Bipolar Disorder. (Word document)
13 December 2006
Directorate Change. (Word document)
07 December 2006
Holding In Company. (PDF document)
31 August 2006
Interim Results 8 Months to 30 June 2006. (PDF document)
30 August 2006
Holding in Company. (PDF document)
14 August 2006
Holding in Company. (PDF document)
14 August 2006
Holding in Company. (PDF document)
11 August 2006
Holding in Company. (PDF document)
20 July 2006
Exercise of Options. (PDF document)
06 July 2006
Change of Name. (PDF document)
06 July 2006
Admission of Curidium Medica plc to AIM. (PDF document)
06 July 2006
Curidium announces the appointment of Dr Smita Price as its new Director of
Psychiatry Research. (PDF document)
12 June 2006
Announcement of the conditional reverse acquisition of Curidium Limited by Cielo Holdings Plc and re-admission of the enlarged group to AIM. (PDF document)
10 October 2005:
Curidium announces exciting commercial opportunities from new research in Schizophrenia and Bipolar disorder. (PDF document)
|
